NMN
Accessible · Evidence and recent research
Notify me when meaningful evidence changes.
Where things stand
NMN is a precursor of NAD, a molecule involved in cellular metabolism. Small human trials have shown that supplementation can raise blood NAD and have examined short-term functional outcomes. These trials do not establish that raising NAD makes people live longer, and brief tolerability findings cannot settle the safety of years of use. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 7, 2026: “Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults”. Its implications have not yet been summarized in a source-checked review. Read update ↗
AI-written overview · not expert-reviewed · Background sources checked Sep 23, 2026 · Recent updates cover the last 30 days of this collection. A new report does not automatically change the evidence assessment.
Background and coverage
- Regulatory status
- Supplement
- Availability
- Limited
- Category
- Accessible
- Human results verified here
- 0
Evidence collection is needs review. 0 approved assessments; 14 assessments awaiting review; 1 published studies with verified results. Safety: not assessed.
Recorded evidence activity (experimental)
A numeric breakdown will be available after baseline review. Safety is not yet assessed.
What changed
Evidence events affecting this intervention
Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
Trial registry update: RECRUITING. No results reported in the supplied registry record.
Systematic review of sex and age differences in ischemic stroke molecular pathology and therapeutic response
This systematic review examined how biological sex and aging shape molecular mechanisms in ischemic stroke, emphasizing sex-specific cell death pathways, mitochondrial dysfunction, and NAD+-sirtuin signaling. The authors describe how premenopausal females show caspase-dependent apoptosis while males exhibit PARP-1-mediated parthanatos, and how postmenopausal females lose neuroprotective advantages due to estrogen receptor changes and mitochondrial decay. The review proposes precision medicine approaches including ER-alpha modulators, NAD+ precursors, and senolytic combinations tailored to sex and reproductive stage.
Metformin has extensive preclinical evidence but limited clinical proof of geroprotective effects in systematic review.
This systematic review examined pharmacological interventions targeting aging pathways, including metformin, from literature published January 2010–May 2026. Metformin and rapamycin had among the most extensive preclinical and translational evidence, but the review found that clinical evidence for broadly applicable geroprotection remains limited. The authors emphasize a substantial gap between mechanistic plausibility and clinically validated geroprotection in humans.
Pilot RCT of metformin-containing combination therapies on healthspan outcomes over 90 days
This was a 90-day randomized controlled pilot trial comparing three arms: control, multi-therapy (including metformin, naltrexone, B12, and NAD+), and comprehensive therapy (including metformin, rapamycin, naltrexone, B12, NAD+, GSH, and other supplements). The study enrolled up to 30 subjects (approximately 10 per arm) to assess effects on longevity-related outcomes. Effect sizes were not reported.
Assessment history
The 25 most recent recorded changes, including corrections and backfill
Human studies with verified results
No published human results verified in this collection yet
Animal and mechanistic evidence
No preclinical studies tracked yet
Clinical trials
Claims
Testable statements and where the evidence stands